GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (NAS:NBSE) » Definitions » Shiller PE Ratio

NeuBase Therapeutics (NeuBase Therapeutics) Shiller PE Ratio : (As of Jun. 02, 2024)


View and export this data going back to 2007. Start your Free Trial

What is NeuBase Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


NeuBase Therapeutics Shiller PE Ratio Historical Data

The historical data trend for NeuBase Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Shiller PE Ratio Chart

NeuBase Therapeutics Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NeuBase Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeuBase Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, NeuBase Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuBase Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where NeuBase Therapeutics's Shiller PE Ratio falls into.



NeuBase Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

NeuBase Therapeutics's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, NeuBase Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.66/129.8595*129.8595
=-0.660

Current CPI (Sep. 2023) = 129.8595.

NeuBase Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -40.000 98.326 -52.828
201403 -40.000 99.695 -52.103
201406 -36.000 100.560 -46.489
201409 -52.000 100.428 -67.239
201412 -72.000 99.070 -94.377
201503 -48.000 99.621 -62.570
201506 -44.000 100.684 -56.750
201509 -52.000 100.392 -67.264
201512 -80.000 99.792 -104.104
201603 -68.000 100.470 -87.891
201606 -96.000 101.688 -122.596
201609 -84.000 101.861 -107.089
201612 -84.000 101.863 -107.087
201703 -84.000 102.862 -106.047
201706 -28.000 103.349 -35.182
201709 -32.000 104.136 -39.905
201712 -29.600 104.011 -36.956
201803 -15.400 105.290 -18.994
201806 -3.800 106.317 -4.641
201809 -44.929 106.507 -54.780
201812 -6.400 105.998 -7.841
201903 -8.000 107.251 -9.686
201906 -8.000 108.070 -9.613
201909 -26.887 108.329 -32.231
201912 -5.200 108.420 -6.228
202003 -5.200 108.902 -6.201
202006 -3.600 108.767 -4.298
202009 -4.000 109.815 -4.730
202012 -3.600 109.897 -4.254
202103 -4.800 111.754 -5.578
202106 -5.800 114.631 -6.570
202109 -4.200 115.734 -4.713
202112 -4.800 117.630 -5.299
202203 -6.000 121.301 -6.423
202206 -5.200 125.017 -5.401
202209 -4.800 125.227 -4.978
202212 -2.600 125.222 -2.696
202303 -2.400 127.348 -2.447
202306 -2.040 128.729 -2.058
202309 -0.660 129.860 -0.660

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NeuBase Therapeutics  (NAS:NBSE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


NeuBase Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuBase Therapeutics (NeuBase Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
Executives
Symetryx Corp 10 percent owner 2828 BATHURST ST #400, TORONTO A6 M6B3A7
Aleta Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
Barry Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
William Roland Mann officer: COO 700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Todd P. Branning officer: Chief Financial Officer C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Sandra Rojas-caro officer: Chief Medical Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746
Kianoush Motesharei officer: See Remarks 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Gerald J Mcdougall director 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Gines Diego Miralles director 2235 VIA FRESCA, LA JOLLA CA 92037
Franklyn G Prendergast director
Dietrich A Stephan director, 10 percent owner, officer: President and CEO 213 SMITHFIELD ST, PITTSBURGH PA 15222
Lipizzaner Llc 10 percent owner 1209 ORANGE STREET, WILMINGTON DE 19801